Procalcitonin and cellulitis:correlation of procalcitonin blood levels with measurements of severity and outcome in patients with limb cellulitis by Brindle, Richard et al.
                          Brindle, R., Ljaz, A., & Davies, P. (2018). Procalcitonin and cellulitis:
correlation of procalcitonin blood levels with measurements of severity and
outcome in patients with limb cellulitis. Biomarkers, 24(2), 127-130.
https://doi.org/10.1080/1354750X.2018.1501764
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1080/1354750X.2018.1501764
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Taylor & Francis at
https://www.tandfonline.com/doi/full/10.1080/1354750X.2018.1501764 . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ibmk20
Biomarkers
ISSN: 1354-750X (Print) 1366-5804 (Online) Journal homepage: http://www.tandfonline.com/loi/ibmk20
Procalcitonin and cellulitis: correlation of
procalcitonin blood levels with measurements
of severity and outcome in patients with limb
cellulitis
R. J. Brindle, A. Ijaz & P. Davies
To cite this article: R. J. Brindle, A. Ijaz & P. Davies (2018): Procalcitonin and cellulitis: correlation
of procalcitonin blood levels with measurements of severity and outcome in patients with limb
cellulitis, Biomarkers, DOI: 10.1080/1354750X.2018.1501764
To link to this article:  https://doi.org/10.1080/1354750X.2018.1501764
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Accepted author version posted online: 27
Jul 2018.
Published online: 23 Aug 2018.




Procalcitonin and cellulitis: correlation of procalcitonin blood levels with
measurements of severity and outcome in patients with limb cellulitis
R. J. Brindlea# , A. Ijazb and P. Daviesc
aDepartment of Clinical Sciences, University of Bristol, Bristol, UK; bEmergency Department, Royal Lancaster Infirmary, University Hospitals of
Morecambe Bay, Lancaster, UK; cGeneral Practice Support Unit, University Hospitals Bristol, Bristol, UK
ABSTRACT
Background: Procalcitonin levels may be raised in bacterial infections and have been used to guide
antibiotic therapy. There is little data on procalcitonin and limb cellulitis.
Objectives: Within a clinical trial of antibiotic therapy, we examined the correlation between clinical
observations, blood tests and local measurements of skin damage, with serum procalcitonin levels.
Methods: The data is from a subset of the patients recruited into a clinical trial of antibiotic therapy
for cellulitis (clindamycin for cellulitis, NCT01876628) whose procalcitonin levels were correlated with
clinical and laboratory measurements. We selected the variables strongly correlated with procalcitonin
and evaluated the predictive value of the baseline procalcitonin on the primary trial outcome.
Results: 136 patients provided 307 procalcitonin levels which were correlated with 8 variables. The
strongest correlations (correlation coefficient of >0.5) with procalcitonin were the affected skin area
(0.537), C-reactive protein (0.574) and neutrophil:lymphocyte ratio (0.567). Receiver operator character-
istic curves demonstrated poor sensitivity and specificity of procalcitonin in predicting primary out-
come. Procalcitonin baseline levels were low but decreased as patients recovered.
Conclusions: Procalcitonin levels are generally low in limb cellulitis and cannot be used to confirm the
diagnosis or the need for antibiotic therapy. Procalcitonin is a poor predictor of early improvement.
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Introduction
Procalcitonin is a biochemical marker which is raised in bac-
terial infections. It is produced in thyroidal C-cells and other
neuroendocrine cells but is also produced by a wide range
of cells of extrathyroidal origin in response to bacterial infec-
tion (Morgenthaler et al. 2003). Procalcitonin blood levels
have been used to assist in determining whether a patient
will benefit from antibiotic therapy and have been used to
withhold antibiotics, as well as to stop antibiotics (Schuetz
et al. 2009). Cellulitis is a common infection of the skin and
procalcitonin has been proposed as a test which could differ-
entiate cellulitis from other inflammatory skin conditions
which may mimic cellulitis (Rast et al. 2015). Procalcitonin
may also have a value in measuring severity of an infection
and thus the duration of the patient’s symptoms and signs,
and as a guide for therapy (Mahmood et al. 2016).
Within a clinical trial of cellulitis (Brindle et al. 2017), we
wanted to examine the relationship between routine blood
tests and local measurements of skin damage, from screen-
ing and enrolment into the trial, to see if a baseline meas-
urement of procalcitonin might be useful. We also measured
levels of procalcitonin on two occasions following antibiotic
therapy. All the procalcitonin levels available were assessed
for their degree of correlation with other objective variables
measured at the same time. We used the most highly corre-
lated variables to compare their sensitivity and specificity
with procalcitonin in achieving primary outcome. We also
wished to see whether renal impairment was associated with
elevated levels of procalcitonin in the study population.
Clinical significance
 There is a published data showing low levels of procalci-
tonin in facial cellulitis.
 There is a retrospective study of cellulitis in which procal-
citonin was correlated with severity and which demon-
strated low levels in some patients with cellulitis.
 This study is of a prospective group within a clinical trial
with sequential sampling for procalcitonin and a pre-
defined outcome.
 It shows that levels of procalcitonin are generally low but
decrease with recovery. Procalcitonin is not a useful pre-
dictor of early improvement.
Patients and methods
This study used data collected as part of a clinical trial of
antibiotic therapy for cellulitis (clindamycin for cellulitis;
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NCT01876628) funded by the UK National Institute for Health
Research (PB-PG-0212-27015) and approved by the UK
National Research Ethics Service (reference number: 13/SC/
0211). The trial compared flucloxacillin with placebo versus
flucloxacillin with clindamycin. The trial results showed no
significant difference between the two antibiotic regimens in
achieving primary outcome; improvement at the Day 5 fol-
low-up visit (Brindle et al. 2017).
A subset of the patients sequentially recruited from two
centres which were offering routine procalcitonin testing
during the latter part of the trial (August 2014 to October
2015), had procalcitonin levels measured at three time
points. Patients with cellulitis who were screened for eligibil-
ity for the trial during this period but were not enrolled did
not provide follow-up samples. Cellulitis was defined using
criteria used in the PATCH trial of cellulitis: local warmth, ten-
derness, or acute pain; unilateral erythema or bilateral ery-
thema, with a temporal association between symptoms and
the more severely affected leg; and unilateral oedema. If
there was doubt about the certainty of the diagnosis, the
patient was excluded (Thomas et al. 2013). At screening, or
following entry into the trial, blood was drawn at Baseline,
Day 5 and Day 10. Procalcitonin was measured using the
VIDASVR or Roche Diagnostics B.R.A.H.M.S PCTTM systems.
The primary outcome was improvement at the Day 5 fol-
low-up visit, defined as being afebrile (<37.5 C) and having a
reduction in limb swelling (measured by limb circumference) or
a reduction in erythema (measured by skin-surface tempera-
ture) of 0.2 standard deviations or more. The reduction in limb
swelling and limb temperature used the difference between
affected and unaffected limbs to reduce confounding by ambi-
ent temperature, clothing and posture. Only patients with all
three values were evaluated for primary outcome in this study.
Medians and geometric (natural logarithm) means have
been reported instead of means where the data is skewed.
Procalcitonin levels were correlated with clinical and laboratory
measurements using the natural logarithm. The size of the cor-
relation coefficient is the degree of correlation between procal-
citonin and a variable; the p value gives the degree of
statistical likelihood that this correlation is true. We selected
those variables which are most strongly correlated (Pearson cor-
relation coefficient of >0.5) with procalcitonin and generated
receiver operator characteristic (ROC) curves to evaluate the
predictive value of the baseline procalcitonin, and the other
variables, on failing to achieve the primary trial outcome. A
ROC curve with high sensitivity and high specificity would have
a large area under the curve (AUC) and the optimum value
would be close to the upper left corner of the chart. Yates cor-
rected Chi-squared test was used for categorical data and a
two-sample independent t-test for equality of means; a p value
of less than 0.05 was regarded as significant. Statistical analysis
and ROC curve generation was done using IBM SPSS Statistics
for Windows, Version 23.0 (IBM Corp., Armonk, NY).
Results
One hundred thirty-six patients were included in this study;
the baseline characteristics are summarized in Table 1. The
characteristics of this subpopulation are similar to the charac-
teristics of the 410 patients included in the trial. The patients
provided 307 procalcitonin values which were correlated
with 8 variables, which are summarized in Table 2. Figure 1
summarizes the patient numbers from screening and enrol-
ment to follow-up, with the median procalcitonin values at
each point. The geometric mean baseline procalcitonin level,
of those with any follow-up levels, was 0.19; reducing to 0.10
at Day 5 and to 0.06lg/L at Day 10. Of the patients enrolling
in the trial, 69 out of 109 (63%) had procalcitonin levels below
0.25lg/L at baseline. One patient had a level of >100 and was
nominated a value of 101lg/L for the analyses. The strongest
correlations with procalcitonin were the total affected skin area,
C-reactive protein and neutrophil:lymphocyte ratio.
77 out of the 93 (83%) patients who were evaluable at
the Day 5 follow-up achieved primary outcome. This is simi-
lar to the whole trial in which 276 out of 328 (84%) evalu-
able patients achieved primary outcome. Of those patients
with procalcitonin levels less than 0.25 mg/L, 52 out of 60
(87%) patients achieved primary outcome compared to 25 of
the 33 (76%) patients with PCT levels greater or equal to
0.25 mg/L; OR 2.08 (95% CI: 0.70–6.19), p¼ 0.297.
Receiver operator characteristic (ROC) curves were gener-
ated to examine the sensitivity and specificity of procalcito-
nin levels and the three most highly correlated variables:
C-reactive protein, neutrophil:lymphocyte ratio and total
affected skin area, against failure to achieve primary out-
come. The higher the procalcitonin level the less likely the
patient was to have improved at Day 5 (Figure 2 and
Table 3). The ROC curve showed that procalcitonin levels
had poor sensitivity and poor specificity for predicting out-
come. Using a cut-off value of 0.25 mg/L or greater for pre-
dicting failure to achieve primary outcome has a sensitivity
of 30% and a specificity of 50%.
The geometric mean procalcitonin of the 24 patients with
serum creatinine levels of 100mmol/L was 0.52lg/L com-
pared to 0.15 lg/L for the 112 patients with creatinine of
<100 mmol/L; (log mean difference; 1.24, 95% CI: 2.11–0.37),
p¼ 0.007. Of the four patients with procalcitonin levels
greater than 10lg/L (actual levels: 10.6, 18.2, 23.3,
>100 lg/L) the geometric mean creatinine was 184 mmol/L
(actual levels: 115, 404, 56, 437mmol/L).
Discussion
This study explores the relationship between procalcitonin
and other variables that were measured within a clinical trial
of limb cellulitis. Procalcitonin has a reputation of being a
valuable biomarker, that has a role in antimicrobial steward-
ship, and we wanted to examine its role in cellulitis. If the
procalcitonin test enabled us to determine that there is an
active bacterial infection, then this would strengthen the
diagnosis of cellulitis and support the use of an antibiotic.
We found that 63% of patients had levels below 0.25 lg/L at
baseline, which is generally regarded as a cut-off value above
which antibiotic therapy is advised (Schuetz et al. 2011).
Though the baseline levels of procalcitonin were generally
low, they did decrease over time and with recovery. This
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strengthens the hypothesis that cellulitis is a paucibacillary
infection with the skin damage being mediated by a variable
repertoire of toxins rather than direct bacterial action. It is
supported by Bertolus (2016) who did not find procalcitonin
to be a useful biomarker for the risk stratification of facial
cellulitis, with only 9% of their patients having procalcitonin
values above this clinical threshold of 0.25lg/L.
There is very limited data on the relationship between
procalcitonin and later outcomes. Noh et al. (2016) looked at
days of hospitalization and showed a significant correlation
with procalcitonin and length of hospitalization, but this was
also true of C-reactive protein and total white cell count.
Given that procalcitonin levels appear proportional to bacter-
ial load one might expect elevated levels in invasive infec-
tions and therefore helpful in distinguishing cellulitis from
necrotizing fasciitis. Kato et al (2017), in a small series, and
Table 1. Baseline characteristics of the patients. (n¼ 136).
Mean (SD) age in years 52.5 (18.3)
Male (%) 94 (69)
Leg affected (%) 102 (75)
Temperature (C); Mean (SD) 37.0 (0.6)
Pulse (beats per minute); Mean (SD) 90 (25)
Systolic blood pressure (mmHg); Mean (SD) 118 (25)
Affected skin area as percentage of body surface area; Median and IQR 5 (5)
Difference in circumference between affected and unaffected limb (cm); Mean (SD) 2.7 (2.3)
Difference in surface temperature between affected and unaffected limb (C); Mean (SD) 2.8 (1.6)
Neutrophil (X 109/L); Median (IQR) 6.1 (5.4)
Lymphocyte (X 109/L); Median (IQR) 1.5 (0.8)
Urea (mmol/L); Median (IQR) 4.8 (2.5)
Creatinine (mmol/L); Median (IQR) 76 (28)
Albumin (g/L); Median (IQR) 35 (8)
C-reactive protein (mg/L); Median (IQR) 38 (106)
Procalcitonin (mg/L); Median (IQR) 0.11 (0.45)
IQR¼ Interquartile range; SD¼ Standard deviation.
1% of total body skin area is approximately 170 cm2; 10% of total body skin area is approximately equal to the area of one
arm or half the area of a leg.N¼ 109, as only those patients enrolled had these measurements.





Total affected skin area (% of body surface area) 0.537 <0.001
Difference in circumference between limbs (cm) 0.395 <0.001
Difference in temperature between limbs (C) 0.294 <0.001
Neutrophils (109/L) (logarithm) 0.456 <0.001
Lymphocytes (109/L) (logarithm) –0.410 <0.001
Creatinine (mmol/L) (logarithm) 0.289 <0.001
C-reactive protein (mg/L) (logarithm) 0.574 <0.001
Neutrophil:Lymphocyte ratio (logarithm) 0.567 <0.001
SIRS score at Baseline (n¼ 111) 0.267 0.005
Paents screened for trial entry 
136 
Median PCT 0.11 (0.45) 
Paents enrolled into trial 
109 
Median PCT 0.12 (0.52) 
Paents evaluable at Day 5 for 
primary outcome 
93 (89 PCT levels) 
Median PCT 0.08 (0.11) 
Paents seen at Day 10 
82 
Median PCT 0.06 (0.07) 
Excluded because of      
>48 hours of a beta-lactam 
anbioc 
27 
Median PCT 0.08 
Did not aend Day 5 visit 
or had missing data 
16 
Paents missing PCT levels 
20 
Did not aend Day 10 visit 
or had missing PCT levels 
11 
Figure 1. Flow diagram of patients tested and numbers of test results with
median procalcitonin (PCT; (mg/L) and interquartile range (IQR) values at
each point.
Figure 2. Receiver operator characteristic (ROC) curves for baseline values of
procalcitonin (PCT), C-reactive protein (CRP), neutrophil:lymphocyte ratio (N/L)
and total affected skin area (ASA) versus primary outcome.
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Na et al (2017), in a larger series, found procalcitonin levels
to be significantly higher in the patients with necrotising fas-
ciitis than in the patients with cellulitis. A limitation of this
study is that we used the primary outcome used for the C4C
trial as the outcome to test the predictive value of procalci-
tonin. This was done to retain compatibility with the trial.
The levels of procalcitonin correlated well with other
measures of severity; the amount of affected skin and
C-reactive protein and this has been previously reported
(Noh et al. 2016). We found the neutrophil:lymphocyte ratio
to be strongly correlated with procalcitonin and better corre-
lated than neutrophil or lymphocyte counts individually. The
potential elevation of procalcitonin levels in renal impair-
ment is recognized and may compromise the value of this
test in cellulitis when transient renal impairment is present
(Meisner et al. 2001). The ROC curve demonstrates the poor
sensitivity and specificity of procalcitonin in predicting lack
of improvement at Day 5, with no procalcitonin level provid-
ing a useful measure of early outcome.
Conclusion
There does not appear to be any extra information from a
procalcitonin test that other routine tests such as C-reactive
protein, neutrophil and lymphocyte counts, and local meas-
urements of skin damage already provided.
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